Reference
Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure Internet Document : 30 May 2022. Available from: URL: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-issues-voluntary-nationwide-recall-one-lot-anagrelide-capsules-usp-05-mg-due-dissolution-test
Rights and permissions
About this article
Cite this article
Anagrelide lot recalled in USA due to dissolution issue. Reactions Weekly 1909, 1 (2022). https://doi.org/10.1007/s40278-022-16288-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-16288-9